Page last updated: 2024-12-11
noviflumuron
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
noviflumuron: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9828359 |
| CHEMBL ID | 1873307 |
| CHEBI ID | 39386 |
| SCHEMBL ID | 26022 |
| MeSH ID | M0468775 |
Synonyms (25)
| Synonym |
|---|
| n-{[3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]carbamoyl}-2,6-difluorobenzamide |
| 121451-02-3 |
| noviflumuron |
| CHEBI:39386 , |
| n-({[3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]amino}carbonyl)-2,6-difluorobenzamide |
| NCGC00163940-01 |
| e99c7tuw20 , |
| benzamide, n-(((3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)amino)carbonyl)-2,6-difluoro- |
| unii-e99c7tuw20 |
| noviflumuron [iso] |
| C18876 |
| SCHEMBL26022 |
| recruit iv |
| recruit iii |
| x-550007 |
| n-(((3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl)amino)carbonyl)-2,6-difluorobenzamide |
| noviflumuron [mi] |
| xde-007 |
| 1-(3,5-dichloro-2-fluoro-4-((rs)-1,1,2,3,3,3-hexafluoropropoxy)phenyl)-3-(2,6-difluorobenzoyl)urea |
| n-[3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-n'-(2,6-difluorobenzoyl)urea |
| CHEMBL1873307 |
| DTXSID0034774 |
| benzamide, n-[[[3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]amino]carbonyl]-2,6-difluoro- |
| Q27119843 |
| n-[[3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]carbamoyl]-2,6-difluorobenzamide |
Research Excerpts
Pharmacokinetics
Noviflumuron was cleared from termites in a first order process with a half-life of approximately 29 d. hexaflumron was much shorter (8-9 d). [14C]
| Excerpt | Reference | Relevance |
|---|---|---|
| " Noviflumuron was cleared from termites in a first order process with a half-life of approximately 29 d, whereas the half-life of hexaflumuron was much shorter (8-9 d)." | ( Laboratory performance and pharmacokinetics of the benzoylphenylurea noviflumuron in eastern subterranean termites (Isoptera: Rhinotermitidae). Dripps, JE; Karr, LL; King, JE; Sheets, JJ, 2004) | 1.47 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Workers of three termite species, Coptotermes formosanus Shiraki (Blattodea: Rhinotermitidae), Coptotermes gestroi (Wasmann) (Blattodea: Rhinotermitidae), and Reticulitermes flavipes (Kollar) (Blattodea: Rhinotermitidae), were force-fed with cellulose media pads treated with 20-hydroxyecdysone (20E) alone and in combination with noviflumuron for 3 d to examine their mortality time trends up to 14 d (including 3-d exposure time)." | ( Mortality Time Trends of Three Subterranean Termite Species When Exposed to 20-Hydroxyecdysone, Alone and in Combination With Noviflumuron. Carnohan, L; Su, NY, 2018) | 0.86 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (4)
| Class | Description |
|---|---|
| benzoylurea insecticide | |
| dichlorobenzene | Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions. |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 19.1180 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID588533 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 44.6684 | 0.0054 | 28.0263 | 1,258.9301 | AID720659 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 49.6137 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (20)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.18
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.18) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||